Indication

Lialda is indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC) and for the maintenance of remission of UC.

Important Safety Information

  • Lialda is contraindicated in patients with known hypersensitivity to salicylates or aminosalicylates or to any of the ingredients of Lialda.
  • Renal impairment, including minimal change nephropathy, acute and chronic interstitial nephritis, and, rarely, renal failure, has been reported with products such as Lialda that contain mesalamine or are converted to mesalamine. It is recommended that patients have an evaluation of renal function prior to initiating use of Lialda and periodically while on therapy. Exercise caution when using Lialda in patients with known renal dysfunction or a history of renal disease.

Read More Below

This site is intended for US health care professionals. Patient Site
For active, mild to moderate ulcerative colitis (UC)

Important Safety Information

Lialda is contraindicated in patients with known hypersensitivity to salicylates or aminosalicylates or to any of the ingredients of Lialda. See Important Safety Information

Lialda® (mesalamine): #1 Prescribed 5-ASA Among Gastroenterologists1

Lialda Dosing Information

Lialda induction of UC remission Lialda induction of UC remission

Lialda tablets, each containing 1200 mg of mesalamine, help to reduce the pill burden of UC treatment.

Recommended Lialda dosages2:

  • For the induction of remission in patients with active, mild to moderate UC, two or four 1.2 g tablets once daily with food
  • For the maintenance of remission in patients with UC, two 1.2 g tablets once daily with food

Mesalamine Delivery

Delayed-Release Coating

  • A gastro-resistant, pH-dependent film of methacrylic acid copolymers covers the MMX Multi Matrix System® core2,3
    Delayed-Release Coating
  • The pH-dependent coating begins to disintegrate at or above pH 6.8, normally in the terminal ileum2,3
    Delayed-Release Coating

The concurrent use of mesalamine with known nephrotoxic agents, including non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of renal reactions. The concurrent use of mesalamine with azathioprine or 6-mercaptopurine can increase the potential for blood disorders.2

See the MMX® technology in action See the MMX technology in action

MMX® Core

  • The tablet core, using MMX Multi Matrix System® technology, contains mesalamine with hydrophilic and lipophilic excipients that provide for extended release of mesalamine2,3
    MMX Core

Extended Release (MMX®)

  • The intestinal fluids interact with hydrophilic excipients, causing the tablet to swell, forming an outer viscous gel mass slowing diffusion of 5-ASA from the tablet core into the colonic lumen3
  • The tablet and its surrounding gel mass progress through the colon, and pieces of the gel mass gradually break away from the core, releasing 5-ASA3
  • Extended Release (MMX)
    Extended Release (MMX)

The clinical relevance of this delivery system has not been established.

Lialda is not made with gluten or lactose.2

Over 6 million prescriptions and counting4
Lialda: a treatment option approved for 10 years to treat active, mild to moderate UC

Back to top Back to top

Back to top Back to top